This biotech company develops novel therapeutics that target the perpetual cycle of inflammation amplified by tissue and organ damage. Their technology aims to treat autoimmune, inflammatory, metabolic, and neurodegenerative diseases by blocking abnormal DNA release and subsequent inflammation.
Funding
Funding not disclosed
Founders
Product
Problem
Many autoimmune, inflammatory, metabolic, and neurodegenerative diseases are driven by a self-perpetuating cycle of inflammation caused by the release of abnormal DNA following tissue and organ damage. Current treatments often fail to address the underlying cause of this inflammation, leading to limited efficacy and potential side effects.
Solution
STANT b.v. is developing novel therapeutics that modulate the STING pathway, a key regulator of immune responses to mislocalized or abnormal DNA. Their proprietary compounds are designed to block the STING pathway with a differentiated mechanism of action, inhibiting the ongoing cycle of inflammation amplified by tissue and organ damage. By targeting the STING pathway, STANT aims to treat diseases such as systemic lupus erythematosus (SLE), cardiovascular diseases, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and chronic inflammatory diseases like kidney disease.
Target Audience
The primary target audience includes patients suffering from autoimmune, inflammatory, metabolic, and neurodegenerative diseases, as well as pharmaceutical companies seeking novel therapeutics in these areas.
Features
- Proprietary compounds that act as STING antagonists
- Differentiated mode of action compared to existing STING inhibitors
- Designed to block the perpetual cycle of inflammation following tissue damage
- Potential application in autoimmune, inflammatory, cardiovascular, metabolic, and neurodegenerative diseases